Ubhubhane Ongathethiyo Okwandisa Ingozi Yesifo Sephepha: Ingxaki Ye-AMR Iyaqhubeka

Ingxelo yamva nje ye-#WHO yesifo sephepha ityhila inyani ecacileyo: zizigidi eziyi-8.2 zeziganeko ezintsha zesifo sephepha ezifunyenwe ngo-2023—elona liphezulu ukususela oko kwaqaliswa ukubekwa kweliso kwihlabathi liphela ngo-1995. Olu nyuko lusuka kwizigidi eziyi-7.5 ngo-2022 lubuyisela isifo sephepha njengeumbulali wezifo ezosulelayo ohamba phambili, idlula i-COVID-19.

Sekunjalo, ingxaki enkulu nangakumbi ifihla oku kuphinda kuvele:ukuxhathisa iintsholongwane (AMR)I-WHO iqikelela ukuba ngo-2050, i-AMR inokubangaubomi obufikelela kwizigidi ezili-10 ngonyakakwihlabathi liphela, apho i-TB enganyangekiyo ngamayeza (DR-TB) iyeyona nto iphambili. Ngo-2019 kuphela, i-AMR yabulala ngokuthe ngqo abantu abayi-1.3 yezigidi—ukudlula i-HIV/AIDS kunye ne-malaria zidibene—kwaye ngokuunobangela wesithathu ophambili wokufa kwihlabathi liphelaNgaphandle kokungenelela, ukufa okuqokelelweyo ngenxa ye-AMR kunokufikelela kwi-2018.Izigidi ezingama-39 ngo-2050, kunye nelahleko kwezoqoqosho ephezuluI-100 trillion yeedola.

Kutheni Ukuxilongwa Kwangethuba Kungenakuxoxiswana Ngalo
Ukunyangeka kwe-TB kuxhomekeke ekubonweni kwangoko kunye neendlela ezifanelekileyo zokusebenzisa amayeza. Nangona kunjalo, ukusetyenziswa gwenxa kwee-antibiotics kuye kwakhawulezisa i-TB engamelani namayeza amaninzi (MDR-TB), nto leyo eguqula usulelo olunyangwayo lube ziintshabalalisi ezibulalayo.

I-TB engamelani namayeza ibangela i-1/3 yokufa kwe-AMR kwihlabathi liphela.

Abantu abadala bajongene nokunyuka kokufa kwabantu abane-AMR(inyuke ngama-80% ukusukela ngo-1990 phakathi kwabantu abadala).

Utshintsho lwemozulu lunokwenzekaUkusasazeka kwe-AMR kuya kuba mandundu nge-2.4% ngo-2050, nto leyo echaphazela iindawo ezinengeniso ephantsi ngokungalinganiyo.

I-WHO ifuna ngokukhawuleza ukuba kubekho izinto ezintsha ekuxilongweni ngokukhawuleza ukuze kuliwe nokusetyenziswa gwenxa kunye nokuvala izikhewu zonyango

 Ikhithi ye-TB eQinisekisiweyo ye-Macro kunye ne-Micro-Test ye-CE: Izixhobo ezichanekileyo zeXesha le-AMR
Isisombululo sethu sihambelana nesicwangciso se-WHO sokuthintela i-AMR ngokuvumelaukufunyanwa ngaxeshanye kosulelo lweTB + i-rifampicin (RIF) + ukumelana ne-isoniazid (INH)—ibalulekile ekunciphiseni i-DR-TB.

Ezona mpawu:

Isantya kunye nokuchanekaIziphumo zifumaneka kwiiyure ezi-2–2.5 xa zitolikwa ngokuzenzekelayo (uqeqesho oluncinci luyafuneka).

Iithagethi eziBanzi:TB: IS6110 gene

Ukumelana ne-RIF: rpoB (507~533)

Ukumelana ne-INH: InhA, AhpC, katG 315

Uvakalelo oluphezulu: Ifumanisa iibhaktheriya ezinokuba li-10/mL (TB) kunye neebhaktheriya ezili-150–200/mL ukuze ifumane iimpawu zokuxhathisa.

I-WHO-Iyahambelana: Ihlangabezana nezikhokelo zolawulo lwe-DR-TB.

Ukuhambelana Okubanzi: Isebenza neenkqubo eziphambili ze-PCR (umz., i-Bio-Rad CFX96, i-SLAN-96P/S).

Kutheni Oku Kubalulekile:
Ukuchongwa ngokukhawuleza kwezakhi zofuzo zokuxhathisa kuthintela ukusetyenziswa kakubi kwee-antibiotics, kunciphisa ukusasazeka kwazo,

Ubizo Lokwenza Isenzo
Ukudibana kokubuya kwesifo sephepha kunye ne-AMR kufuna izixhobo ezidibanisa isantya ngokuchanekileyo. Isixhobo sethu sivala esi sikhewu—siqinisekisa ukuba unyango luqala ngokuchanekileyo, okokuqala.

Funda nzulu:
https://www.mmtest.com/mycobacterium-tuberculosis-nucleic-acid-and-rifampicin%ef%bc%8cisoniazid-resistance-product/
Qhagamshelana:marketing@mmtest.com

#IVD #PCR #AMRCrisis #Ukumelana namayeza #TB #ENDTB #MDRTB #Uxilongo #Impilo yeHlabathi #WHO #Uvavanyo lweMacroMicro